Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

This study tests whether adding low-dose radiation therapy to a combination of immunotherapy (AK104) and chemotherapy improves outcomes for patients with extensive-stage small cell lung cancer — an aggressive form of lung cancer that has spread beyond one side of the chest. **You may be eligible if...** - You are between 18 and 80 years old - You have been confirmed to have extensive-stage small cell lung cancer - You are in good enough health to tolerate chemotherapy, immunotherapy, and radiation **You may NOT be eligible if...** - Your cancer is limited-stage (confined to one side of the chest) - Your organ function is too impaired to tolerate combination treatment - You have active autoimmune disease or other conditions that prevent immunotherapy Talk to your doctor to see if this trial is right for you.